UB Paderborn / Katalog / Suche / in CDI

Checkpoint inhibitors in breast cancer – Current status

Cancer treatment reviews, 2018-02, Vol.63, p.122-134

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

The lancet oncology, 2022-10, Vol.23 (10), p.e450-e458

2022

Link zum Volltext

Verfügbarkeit prüfen

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Journal of translational medicine, 2012-08, Vol.10 (1), p.169-169, Article 169

2012

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The lancet oncology, 2015-04, Vol.16 (4), p.375-384

2015

Link zum Volltext

Verfügbarkeit prüfen

The real‐world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

International journal of cancer, 2019-12, Vol.145 (11), p.3173-3174

2019

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

The lancet oncology, 2017-05, Vol.18 (5), p.611-622

2017

Link zum Volltext

Verfügbarkeit prüfen

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Nature (London), 2020-01, Vol.577 (7791), p.561-565

2020

Link zum Volltext

Verfügbarkeit prüfen

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Nature communications, 2017-11, Vol.8 (1), p.1738-1738, Article 1738

2017

Link zum Volltext

Verfügbarkeit prüfen

The Universal Character of the Tumor-Associated Antigen Survivin

Clinical cancer research, 2007-10, Vol.13 (20), p.5991-5994

2007

Link zum Volltext

Verfügbarkeit prüfen

Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

Drug discovery today, 2015-09, Vol.20 (9), p.1127-1134

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e006755

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

European journal of cancer (1990), 2023-02, Vol.180, p.125-133

2023

Link zum Volltext

Verfügbarkeit prüfen

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy

Journal for immunotherapy of cancer, 2023-08, Vol.11 (8), p.e006941

2023

Link zum Volltext

Verfügbarkeit prüfen

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e003499

2021

Link zum Volltext

Verfügbarkeit prüfen

Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis—authors' reply

Alimentary pharmacology & therapeutics, 2023-01, Vol.57 (1), p.152-153

2023

Link zum Volltext

Verfügbarkeit prüfen

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e005111

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

Nature communications, 2017-09, Vol.8 (1), p.707-10, Article 707

2017

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers for response to TIL therapy: a comprehensive review

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008640

2024

Link zum Volltext

Verfügbarkeit prüfen

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase

PloS one, 2012-04, Vol.7 (4), p.e34568-e34568

2012

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008372

2024

Link zum Volltext

Verfügbarkeit prüfen

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

The Journal of clinical investigation, 2022-01, Vol.132 (2)

2022

Link zum Volltext

Verfügbarkeit prüfen

CTLA-4 blockade boosts the expansion of tumor-reactive CD8 + tumor-infiltrating lymphocytes in ovarian cancer

Scientific reports, 2020-03, Vol.10 (1), p.3914-3914, Article 3914

2020

Link zum Volltext

Verfügbarkeit prüfen

36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A41-A41

2023

Link zum Volltext

Verfügbarkeit prüfen

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e006432

2023

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Checkpoint inhibitors in breast cancer – Current status

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The real‐world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

The Universal Character of the Tumor-Associated Antigen Survivin

Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis—authors' reply

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

Biomarkers for response to TIL therapy: a comprehensive review

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

CTLA-4 blockade boosts the expansion of tumor-reactive CD8 + tumor-infiltrating lymphocytes in ovarian cancer

36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma

Suchergebnisse filtern